Try our Advanced Search for more refined results
Life Sciences
- 
									October 29, 2025
									3 Pharmaceutical Firms Will Pay $4M To Tribes In Opioid MDLIndivior, Sun Pharmaceuticals and Zydus Pharmaceuticals have inked deals to compensate tribes for their role in the opioid crisis, according to stipulated dismissals entered on Wednesday in Ohio federal court. 
- 
									October 29, 2025
									Brothers Found Guilty Of $100M HIV Drug FraudA Florida federal jury on Wednesday convicted two Maryland brothers accused of conspiring to distribute about $100 million worth of misbranded HIV drugs, finding them guilty of fraud charges related to selling the medication with fake tracing documents. 
- 
									October 29, 2025
									PE-Backed Medical Supplies Giant Medline Files For IPOPrivate equity-backed medical supplies giant Medline has filed for its long-awaited initial public offering, eyeing a return to public markets four years after being taken private through a large buyout. 
- 
									October 29, 2025
									'Smart Drugs' Amphetamine Suit Moves Forward Minus ExecsA Washington federal judge declined to trim claims from a former army nurse's suit alleging that Thesis "smart drugs" contained amphetamines without warning consumers, while dismissing her claims against two executives for the company. 
- 
									October 29, 2025
									3 Firms Guide Thermo Fisher On $8.9B Clario DealThermo Fisher Scientific Inc. said on Wednesday it will acquire Clario Holdings Inc., a provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg, Nordic Capital, Novo Holdings and Cinven for $8.875 billion in cash. 
- 
									October 28, 2025
									Off-Label Prescribing Was Common, Novo Nordisk Tells JuryA whistleblower suing drugmaker Novo Nordisk for allegedly defrauding Washington state's Medicaid system acknowledged from the witness stand Tuesday that she previously prescribed hemophilia drugs for off-label use in her own practice — despite concerns she raised in her lawsuit about other doctors' off-label prescription of Novo Nordisk's drug NovoSeven. 
- 
									October 28, 2025
									Apple Spared From Some Masimo Patent Claims Before TrialA California federal judge issued a mixed ruling in Masimo's case claiming Apple infringed its patents covering pulse oximetry technology for smartwatches, dismissing certain infringement theories but preserving other parts of the case for next week's trial. 
- 
									October 28, 2025
									Perceptive Asks Chancery To Block Kindbody Ex-CEO's NY SuitAttorneys for senior lenders to nationwide fertility clinic chain Kindbody Inc. told a Delaware vice chancellor Tuesday that amendments to a former CEO's suit against the company's controlling lenders and directors in New York triggered a right to pull the dispute into Delaware's Court of Chancery. 
- 
									October 28, 2025
									Trump Admin Ordered To Halt Some Shutdown-Linked LayoffsA California federal judge on Tuesday granted a preliminary injunction to eight unions for federal workers who lost their jobs during the government shutdown, saying they were likely to succeed on their claims that the Trump administration's actions were "political retribution" and unlawful. 
- 
									October 28, 2025
									Bias Claims From Worker Who Failed Drug Test Can ProceedA Pennsylvania federal judge narrowed, but didn't throw out, a disability bias suit from a hospital worker who said he was fired after failing a drug test because he took cannabidiol gummies for a spinal condition, saying a reasonable jury might conclude his disability earned him harsher treatment. 
- 
									October 28, 2025
									Activists Drop Challenge To FDA Inaction On Menthol CigsA lawsuit accusing the U.S. Food and Drug Administration of slow-walking the Biden administration's proposed ban of menthol cigarettes was voluntarily dismissed, months after the Trump administration withdrew the ban entirely. 
- 
									October 28, 2025
									J&J Hit With $20M Verdict In Fla. Talc TrialA Florida jury on Tuesday awarded $20 million to the widow of a nephrologist who used Johnson & Johnson talcum powder for 50 years and died of mesothelioma, after a plaintiffs lawyer argued the company broke its "promise of purity." 
- 
									October 28, 2025
									Exactech Gets Another $19M In DIP Funds Ahead Of SaleJoint implant maker Exactech Inc. received a Delaware bankruptcy judge's permission Tuesday to borrow an additional $19.1 million in its Chapter 11 case as the company works to complete an asset sale by the end of the week. 
- 
									October 28, 2025
									Ex-Philips CEO Can't Undo Finding He Misled ShareholdersA Brooklyn federal judge will not reverse a finding that a former CEO of health technology company Koninklijke Philips NV misled shareholders about the safety and compliance of a subsidiary's sleep and respiratory care products. 
- 
									October 28, 2025
									Akin Beats Malpractice Claim Over Alleged IP Theft PlotA Third Circuit panel on Tuesday refused to revive a malpractice claim against Akin Gump Strauss Hauer & Feld LLP lodged in a lawsuit that accused attorneys of manipulating patent litigation to steal a former Cornell University graduate student's DNA sequencing intellectual property. 
- 
									October 28, 2025
									4th Circ. Overturns Landmark W.Va. Opioid VerdictThe Fourth Circuit on Tuesday overturned a key ruling by a West Virginia judge in the first federal bellwether in multidistrict opioid litigation that went in favor of the country's three biggest drug distributors, finding that the oversupply of opioids can create a public nuisance. 
- 
									October 28, 2025
									Greenberg Traurig Adds Faegre Drinker Mass Tort Pro In NJGreenberg Traurig LLP added to its products liability and pharmaceutical practices in New Jersey this week with the addition of a litigator and trial attorney from Faegre Drinker Biddle & Reath LLP who specializes in complex mass tort cases. 
- 
									October 28, 2025
									Texas Accuses Tylenol Makers Of Hiding Autism DangerThe Texas Attorney General's Office on Tuesday sued the makers of Tylenol, alleging they hid the risk that the drug could lead to autism while marketing acetaminophen as the safest pain relief option for pregnant women and young children. 
- 
									October 27, 2025
									Whistleblower 'Horrified' By Novo Nordisk Drug Sales TacticsThe whistleblower behind a federal lawsuit accusing Novo Nordisk of paying kickbacks to doctors and patients as part of a scheme to drive sales of its hemophilia drug NovoSeven took the witness stand Monday, telling jurors she was "horrified" at how the drugmaker's marketing team targeted doctors. 
- 
									October 27, 2025
									Bros. Had No Fraud Intent In HIV Drug Scam, Fla. Jury ToldTwo Maryland brothers accused of orchestrating a roughly $100 million misbranded HIV drug scheme told a Florida federal jury Monday they had no intent to defraud, saying they were deceived by a co-conspirator who they made a partner in their company. 
- 
									October 27, 2025
									Teva To Pay $35M In Suit Over Delayed Generic InhalersTeva Pharmaceuticals will pay $35 million to resolve claims from a coalition of union healthcare funds that say the company schemed to delay generic competition for its QVAR asthma inhalers, according to a motion for preliminary injunction filed in Massachusetts federal court. 
- 
									October 27, 2025
									Acadia Pushes For Appeal Of Investors' Partial Early WinAcadia Healthcare Company Inc. is looking to appeal a partial early win granted to a proposed class of investors accusing the company of misleading them about the strength of its United Kingdom operations, arguing that the court's recent ruling presents controlling questions of law warranting immediate appellate review. 
- 
									October 27, 2025
									LifeScan Gets Final OK On Ch. 11 Plan After Deal With PBMsA Texas bankruptcy judge on Monday granted confirmation of LifeScan Global Corp.'s Chapter 11 plan after the debtor reached an agreement with pharmacy benefit managers that resolved their objections, allowing the glucose-monitor maker to complete a deal to cut about $1.4 billion of debt. 
- 
									October 27, 2025
									Feds Fight Union Bid To Protect Jobs During Gov't ShutdownThe Trump administration is fighting a group of unions' request for a California federal judge to block the government from laying off federal workers during the shutdown, saying the injunction request from eight unions is far too broad. 
- 
									October 27, 2025
									Fed. Circ. Won't Revive Heart Valve IP Suit Against EdwardsEdwards Lifesciences won't have to face infringement litigation from Aortic Innovations over heart valve transplant technology, the Federal Circuit affirmed Monday. 
Expert Analysis
- 
								Series Writing Novels Makes Me A Better Lawyer  Writing my debut novel taught me to appreciate the value of critique and to never give up, no matter how long or tedious the journey, providing me with valuable skills that I now emphasize in my practice, says Daniel Buzzetta at BakerHostetler. 
- 
								
								SDNY OpenAI Order Clarifies Preservation Standards For AI  The Southern District of New York’s recent order in the OpenAI copyright infringement litigation, denying discovery of The New York Times' artificial intelligence technology use, clarifies that traditional preservation benchmarks apply to AI content, relieving organizations from using a “keep everything” approach, says Philip Favro at Favro Law. 
- 
								
								What 9th Circ.'s Rosenwald Ruling Means For Class Actions  The Ninth Circuit's recent decision in Rosenwald v. Kimberly-Clark has important implications around the Class Action Fairness Act and traditional diversity jurisdiction — both for plaintiff-side and defense-side class action litigators — and deepens the circuit split concerning the use of judicial notice to establish diversity, says Grace Schmidt at DTO Law. 
- 
								
								Trends In Post-Grant Practice Since USPTO Denial Guidance  Six months after the U.S. Patent and Trademark Office updated its guidance on discretionary denial of inter partes review and post-grant review, noteworthy trends in denial statistics have emerged, warranting a reassessment of strategies for parallel proceedings, says Andrew Ramos at Bayes. 
- 
								
								USPTO Under Squires: A Look At The First Month  New U.S. Patent and Trademark Office Director John Squires' opening acts — substantive and symbolic — signal a posture that is more welcoming to technological improvements and focused on rebalancing the office's gatekeeping role, say attorneys at Seyfarth. 
- 
								Opinion Expert Reports Can't Replace Facts In Securities Fraud Cases  The Ninth Circuit's 2023 decision in Nvidia v. Ohman Fonder — and the U.S. Supreme Court's punt on the case in 2024 — could invite the meritless securities litigation the Private Securities Litigation Reform Act was designed to prevent by substituting expert opinions for facts to substantiate complaint assertions, say attorneys at A&O Shearman. 
- 
								Opinion High Court, Not A Single Justice, Should Decide On Recusal  As public trust in the U.S. Supreme Court continues to decline, the court should adopt a collegial framework in which all justices decide questions of recusal together — a reform that respects both judicial independence and due process for litigants, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware. 
- 
								Series Traveling Solo Makes Me A Better Lawyer  Traveling by myself has taught me to assess risk, understand tone and stay calm in high-pressure situations, which are not only useful life skills, but the foundation of how I support my clients, says Lacey Gutierrez at Group Five Legal. 
- 
								
								Latest PTAB Moves Suggest A Subtle Recalibration  Recent decisions from the Patent Trial and Appeal Board, as U.S. Patent and Trademark Office Director John Squires transitions into his new role, offer new procedural and substantive tools for patent owners in procuring patent rights and enforcing them against would-be petitioners, say attorneys at Morgan Lewis. 
- 
								Opinion DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable  In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz. 
- 
								
								Del. Ruling Reaffirms High Bar To Plead Minority Control  The Delaware Court of Chancery's recent decision in Witmer v. Armistice maintains Delaware's strict approach to control and provides increased predictability for minority investors in their investment and corporate governance decisions, says Elena Davis at Ropes & Gray. 
- 
								Series Law School's Missed Lessons: Client Service  Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale. 
- 
								
								How Occasional Activists Have Reshaped Proxy Fights  The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo. 
- 
								
								What To Expect After FDA Warnings To GLP-1 Compounders  The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane. 
- 
								
								Where 4th And 9th Circ. Diverge On Trade Secret Timing  Recent Fourth and Ninth Circuit decisions have revealed a deepening circuit split over when plaintiffs must specifically define their alleged trade secrets, turning the early stages of trade secret litigation into a key battleground and elevating the importance of forum selection, say attorneys at Skadden.